返回 
加入收藏
补肺活血胶囊联合阿奇霉素片治疗COPD稳定期患者的临床观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | 补肺活血胶囊联合阿奇霉素片治疗COPD稳定期患者的临床观察 |
| TITLE： | |
| 摘要： | 目的：观察补肺活血胶囊联合阿奇霉素片治疗慢性阻塞性肺疾病（COPD）稳定期患者的效果和安全性。方法：选取2014年6月－2018年2月安徽省胸科医院收治的COPD稳定期患者140例，按随机数字表随机分为对照组和观察组，各70例。两组患者均行戒烟干预及对症处理，对照组在此基础上给予噻托溴铵粉雾剂1吸，每日1次+阿奇霉素片0.25 g，每周2次；观察组患者在对照组基础上加用补肺活血胶囊4粒，每日3次。两组患者均连续治疗180 d。观察两组患者的临床疗效以及治疗前后血清炎症因子[C反应蛋白（CRP）、白细胞介素6（IL-6）、肿瘤坏死因子α（TNF-α）]水平、肺功能相关指标[最大呼气流量（PEF）、第1秒用力呼气量（FEV1）、第1秒用力呼气量占用力肺活量百分率（FEV1/FVC）]、COPD相关症状[慢性阻塞性肺疾病急性加重（AECOPD）发作次数、6 min步行距离（6MWT）]，并记录不良反应发生情况。结果：对照组患者有9例脱落，观察组有3例脱落，共有128例（对照组61例、观察组67例）完成本研究。观察组患者的总有效率为92.54％，显著高于对照组的80.33％（P＜0.05）。治疗前，两组患者血清炎症因子水平、肺功能相关指标、COPD相关症状比较，差异均无统计学意义（P＞0.05）。治疗后，两组患者血清CRP、IL-6、TNF-α水平均显著降低，AECOPD发作次数均显著减少，且观察组显著低于或少于对照组；两者患者PEF、FEV1、FEV1/FVC均显著升高，6MWT均显著延长，且观察组显著高于或长于对照组（P＜0.05）。对照组有1例患者出现皮疹，观察组有2例出现轻度恶心，但均未见严重不良反应发生。结论：补肺活血胶囊联合阿奇霉素片可显著降低COPD稳定期患者的血清炎症因子水平，改善其肺功能，缓解其临床症状，且安全性较高。 |
| ABSTRACT： | OBJECTIVE： To observe the efficacy and safety of Bufei huoxue capsules combined with Azithromycin tablets in the treatment of patients with stable COPD. METHODS： Totally 140 patients with stable COPD were collected from Anhui Chest Hospital during Jun. 2014-Feb. 2018， and then divided into control group and observation group according to random number table， with 70 cases in each group. Both groups received smoking cessation intervention and symptomatic treatment. Control group was additionally given Tiotropium bromide powder for inhalation， once a day+Azithromycin tablets 0.25 g， twice a week. Observation group were additionally given Bufei huoxue capsules 4 pills， 3 times a day， on the basis of control group. Both groups were treated for 180 d continuously. The clinical efficacies of 2 groups were observed， and the levels of serum inflammatory factors （CRP， IL-6 and TNF-α）， lung function related indexes （PEF， FEV1 and FEV1/FVC） and COPD related symptoms （time of AECOPD attack and 6MWT） were observed before and after treatment. The occurrence of ADR was recorded. RESULTS： Totally 9 cases withdrew from the study in control group， and 3 cases in observation group. A total of 128 cases （61 cases in control group， 67 cases in observation group） completed the study. Total response rate was 92.54％ in observation group， which was significantly higher than 80.33％ in control group（P＜0.05）. Before treatment， there was no statistical significance in the levels of serum inflammatory factors， lung function related indexes or COPD related symptoms （P＞0.05）. After treatment， the levels of CRP， IL-6 and TNF-α in 2 groups were decreased significantly， and the times of AECOPD attack were decreased significantly； observation group was significantly lower or less than control group. PEF， FEV1 and FEV1/FVC were increased significantly in 2 groups and 6MWT was prolonged significantly； observation group was significantly higher or longer than control group （P＜0.05）. One case suffered from skin rash in control group， and two cases had mild nausea in observation group； no severe ADR was found in both groups. CONCLUSIONS： Bufei huoxue capsules combined with Azithromycin tablets can significantly reduce the level of serum inflammatory factors of stable COPD patients， improve their lung function， and relieve clinical symptoms with good safety. |
| 期刊： | 2019年第30卷第10期 |
| 作者： | 夏文娟，梅晓冬，王学中 |
| AUTHORS： | XIA Wenjuan， MEI Xiaodong，WANG Xuezhong |
| 关键字： | 补肺活血胶囊；阿奇霉素片；慢性阻塞性肺疾病稳定期；肺功能；炎症因子；相关症状 |
| KEYWORDS： | Bufei huoxue capsules； Azithromycin tablets； Stable COPD； Lung function； Inflammatory factors； Related symptoms |
| 阅读数： | 527 次 |
| 本月下载数： | 11 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
